ST Pharm's History
Technology-driven gene therapy CDMO
from oligonucleotide to xRNA
- Establishment of Samchully Pharmaceutical Co.
1983
1988 – 2009
Breaking ground
1988
1988 – 2004
- Supplied anti–HIV/AIDS key intermediate (Thymidine) to big pharmas (GSK, BMS) * World-largest supplier of Thymidine (dT)
2000
2000 – 2012
- Supplied API (Zidovudine, 1st HIV/AIDS drug) to GSK * Largest global supplier of nucleosides by early 2000s
2002
2002 – 2013
- Supplied API intermediate (Telbivudine, HBV drug) partnering with Novartis
- Completed Oligonucleotide facility (Pilot scale)
2003
2004
2007
2007 – 2020
- Supplied API (HCV Drug) to Roche
- Supplied API intermediate (Atazanavir, HIV, AIDS drug) to BMS
2010 – 2019
Strengthen the Flagship Business
- Became a subsidiary of Dong-A Socio Group
(ST PHARM)
2010
- Became a subsidiary of Dong-A Socio Group
- Nominated as Innovative Pharmaceutical Company
2012
- Selected as Advanced Technology Center (ATC)
2013
2013 – 2020
- Supplied API of first HCV cure drug for commercial use to Client G
- TGA (Austrailia) cGMP certification
2014
- Establishment of second manufacturing site (Ban-wol site)
- FDA cGMP certification and PMDA cGMP certification
2015
2015 – 2020
- Supplied Oligo API for clinical trials
- EU cGMP certification
- Awarded for $100,000,000 of exportation
- IPO in KOSDAQ (KOSDAQ: 237690), Presidential Award for Innovative Company
2016
- Strategic expansion of Oligonucleotide (Oligo)
- Honored with Global Growth Excellence Leadership Award (Frost & Sulivan)
2018
- Non-clinical animal safety CRO service started AnaPath Services (Switzerland) & AnaPath Research (Spain)
- IND filing of STP1002(anti-cancer drug) in USA
2019
2020 – Present
Expanding business portfolio
2019
- Supplied Oligo API for clinical trial phase III
- Roche CDMO Award 2019
- Approval of STP0404(AIDS) Phase1(EU) IMPD
- Expansion of Oligo plant (1st : 0.8t scale / 2nd : 0.3t scale)
- mRNA business started
2020
2020 – Present
- Supplied Oligo API for commercial use
- Establishment Levatio Therapeutics (mRNA & CAR-NKT R&D Center)
- Mid-scale mRNA GMP facility in Banwol Campus
2021